Plant Health Care PLC
15 January 2007
For immediate release 15 January 2007
Plant Health Care plc
('PHC' or 'the Group')
Myconate produces impressive yield gains in corn and soybeans in 2006
Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, is pleased to report the success of its Myconate test
programmes for corn and soybeans in 2006. Building upon the impressive results
in these crops from prior years, the results of this year's trials further
validate the effectiveness of Myconate in increasing yields in these two key
crops.
During 2006 Myconate was evaluated in a large number of corn trials in the USA
and France as well as in many soybean trials in the USA. These trials were
distributed across the appropriate growing areas for the crops in the different
countries, to provide a range of soil, climate and cultural conditions, as well
as across a range of crop varieties. These extensive trials are summarised
below.
Corn in the USA:
----------------
PHC and independent evaluators carried out 27 separate Myconate trials spread
across the Midwest, from Iowa east to Ohio and Minnesota and south to Illinois.
Despite very high yields in the control plots (194 bu/acre against a normal
average of 155 bu), in 23 of the trials (85%) there was an increase in yield.
The average yield increase over all trials was 6 bu/ac (3%) with greater
increases occurring most often in more normal yielding fields.
Corn in France:
---------------
12 trials throughout France demonstrated increases with Myconate in both grain
weight and number. In a record year at Masset (12t/ha), yield component analysis
demonstrated a 9.5% increase in grains per cob and a 5.8% increase in grain
weight. When adjusted for plant populations this accounted for a 15% increase in
yield. Yield component analysis of a trial in the south-east showed a 10.2%
increase in grains per ear.
Soybeans in the USA:
--------------------
PHC and independent evaluators carried out 33 separate soybean trials across the
Midwest. In 23 of the trials (70%) there was an increase in yield even though
the average trial yield for the untreated plots was high at 55 bu/acre. The
average yield increase over all trials was 6%.
Our trials continue to generate interest in Myconate in its target markets prior
to commercial rollout. Attention is now being directed to other crops; for
example Myconate trials with winter wheat have already been established in two
Midwest states in the USA.
The Company will shortly be providing a post year end trading update and will,
at that time, also provide a further update on the process of evaluating
potential partners for the rollout of Myconate.
John Brady, CEO of Plant Health Care commented on the results, 'The 2006 trials
results further validate efficacy of Myconate, and demonstrate the ability to
replicate positive results in a consistent manner. We will now begin to expand
our testing parameters to include other major crops such as wheat and the small
cereal grains. We have had strong interest from a number of potential partners
and remain confident of securing a major partner for this important product.'
PHC's novel Myconate technology helps crops to develop larger root mass, through
the stimulation of mycorrhizal fungi, Myconate works by triggering the
colonisation of beneficial micro-organisms called mycorrhizal fungi. With more
mycorrhizal fungi at work, each plant can draw more nutrients and moisture out
of the soil. More nutrients make for healthier plants, and significantly
greater overall yields. The Board believes Myconate could be the key to
changing the face of farming. The safety and ease of application of Myconate
means that management practices need not be over-hauled. The procedure is a
straightforward blending process, either tank mixing the Myconate with the
fertilizer during planting, or applying the Myconate to the seed before
planting.
-ends-
For further information:
Plant Health Care plc
John Brady, CEO Tel: 001 603 525 3702
Tavistock Communications Tel: 020 7920 3150
Jeremy Carey/Simon Compton
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.